Controlled gene therapy to reverse Rett syndrome

First controlled gene therapy for Rett syndrome using next-generation CNS delivery.

Get in touch

Get in touch

Our therapy

Our therapy

Blur Glow
White Glow

Indication

One of the largest genetic rare diseases in the world - and still no cure

One of the largest genetic rare diseases in the world - and still no cure

Children develop normally for 6-12 months then progressively lose hand use, speech, and motor function. The only approved drug has unclear efficacy, significant side effects and does not correct the cause of the disease. Competitive products do not reach most cells in the brain and do not control gene expression in different types of brain cells as well as our product.

Children develop normally for 6-12 months then progressively lose hand use, speech, and motor function. The only approved drug has unclear efficacy, significant side effects and does not correct the cause of the disease. Competitive products do not reach most cells in the brain and do not control gene expression in different types of brain cells as well as our product.

1 in 0

girls born with Rett syndrome

1 in 0

girls born with Rett syndrome

0

patients worldwide

0

patients worldwide

0B+

annual market potential

0B+

annual market potential

Our therapy

A best-in-class therapy that controls the dose, matches the cell type, and reaches the whole brain

Rett syndrome traces to a single gene, MECP2. Reverta restores it the way a healthy body would.

Full-length gene

The complete MECP2 gene, not a shortened version, so it can do its full job.
Dot Background

Controlled dose

Built-in regulation holds expression in the correct therapeutic window and avoids the overexpression that has limited other approaches.
Dot Background

Whole-brain delivery

One intravenous infusion carries the gene across the whole brain. More effective, minimally invasive, no neurosurgery.
Dot Background

Cell-type matching

Expression matches how each brain cell naturally uses the gene, instead of one dose for all.
Dot Background

Where we are

Our science works and the data is strong. Now it is all about execution

We have finished the research phase and confirmed the approach in disease models. The program is now in preclinical development, with a defined path to first-in-human trials.

✓
Completed
Research
Complete. Approach confirmed in disease models.
◐
In Progress
Preclinical
Underway. Building toward an IND-enabling package.
Upcoming
Clinic
Next. First-in-human trial in Rett syndrome.
✓
Completed
Research
Complete. Approach confirmed in disease models.
◐
In Progress
Preclinical
Underway. Building toward an IND-enabling package.
Upcoming
Clinic
Next. First-in-human trial in Rett syndrome.

Partners

Partnering with the best in the field

Partnering with the best in the field

We are proud to collaborate with those who drive change. These partnerships reflect our shared commitment to turning science into real-world impact and reverse Rett Syndrome.

We are proud to collaborate with those who drive change. These partnerships reflect our shared commitment to turning science into real-world impact and reverse Rett Syndrome.

RESEARCH PARTNERSHIP

The largest worldwide funder of Rett research and leading partner for genetic medicine scientists and companies.

Website

Website

INVESTOR

Extend is a multidisciplinary technology transfer platform dedicated to transforming life sciences research into impactful biotech startups.

Website

Website

Team

A purpose-built team of world class researchers and serial entrepreneurs

More than 60 years of combined gene therapy experience across science, clinical development, regulatory affairs, and manufacturing.

Jeffery S. Vick

CO-FOUNDER & CEO

Co-founder of four biotechs and a former biotech CEO, with deep experience scaling gene therapy companies.

Vania Broccoli

CCO-FOUNDER & SCIENTIFIC ADVISOR

Head of Stem Cells and Neurogenesis at the San Raffaele Scientific Institute and a leading MECP2 researcher.

Carlo Bertozzi

CO-FOUNDER & CHAIRMAN

Founder and chief executive of multiple biotechnology companies across Europe.

Mary Newman

ADVISOR, CLINICAL & REGULATORY

Former chief development officer and senior regulatory leader in gene therapy.

Matthias Hebben

ADVISOR, CMC & MANUFACTURING

Gene therapy technology and manufacturing leader, formerly head of AAV technology and CMC at a leading institute.

Our vision

We are building for a future where a genetic diagnosis is no longer a life sentence

We are building for a future where a genetic diagnosis is no longer a life sentence

A disease caused by a single gene should be curable at its source. With Rett syndrome, Reverta is proving that gene therapy can be precise, controlled, and safe.

A disease caused by a single gene should be curable at its source. With Rett syndrome, Reverta is proving that gene therapy can be precise, controlled, and safe.

We are currently raising our Series A to finally develop a cure for Rett.

If you are interested to invest or partner with us, don't hesitate to reach out.

Get in touch

Get in touch

Blur Glow
White Glow

Indication

Therapy

Development

Team

© 2026 Reverta. Developing controlled gene therapy for Rett syndrome. This site is for general information only and does not constitute medical advice or an offer of securities.